Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: Assessment using methyl-paraoxon

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 8, 2012, Pages 1052-1060

  Lorke, Dietrich E ^a,b   Hasan, Mohamed Y ^b   Nurulain, Syed M ^b   Shafiullah, Mohamed ^b   Kuča, Kamil ^c   Petroianu, Georg A ^a,b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Carbamates; Cholinesterase; Cox analysis; Methyl paraoxon; Organophosphate; Oximes; Pretreatment; Prophylaxis; Rat

Indexed keywords

7 METHOXYTACRINE; AMILORIDE; CHOLINESTERASE INHIBITOR; K 27; METHYLENE BLUE; METOCLOPRAMIDE; PARAOXON; PHYSOSTIGMINE; PYRIDOSTIGMINE; RANITIDINE; TACRINE; TIAPRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; IC 50; LD 50; MALE; MORTALITY; NEUROPROTECTION; NONHUMAN; RAT; RISK; SURVIVAL;

ANIMALS; CHOLINESTERASE INHIBITORS; LETHAL DOSE 50; MALE; MORTALITY; NEUROPROTECTIVE AGENTS; ORGANOPHOSPHATES; PARAOXON; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84875025892     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311211080016     Document Type: Article

References (60)

1. Antonijevic, B.; Stojiljkovic, M.P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res., 2007, 5 (1), 71-82.
2. Kaminski, J.J.; Bodor, N.; Higuchi, T. N-halo derivatives III: stabilization of nitrogen-chlorine bond in N-chloroamino acid derivatives. J. Pharm. Sci., 1976, 65 (4), 553-557.
3. Kusic, M.; Gavrilovic, M.; Mihajlovic, M.; Boskovic, B. [Results of 6 months, therapy of familial hypercholesterolemia (hyperlipoproteinemia type II) with colestipol]. Srp. Arh. Celok. Lek., 1980, 108 (9), 875-881.
4. Gupta, R.C. In: Toxicology of organophosphate and carbamate compounds; Gupta, Ed.; Elsevier Academic Press: Amsterdam, Boston, Heidelberg, 2006; pp. 5-24.
5. McCauley, L.A. In: Toxicology of organophosphate and carbamate compounds; Gupta, Ed.; Elsevier Academic Press: Amsterdam, Boston, Heidelberg, 2006; pp. 69-78.
6. Watson, A.; Bakshi, K.; Opresko, D.; Young, R.; Hauschild, V.; King, J. In: Toxicology of organophosphate and carbamate compounds; Gupta, Ed.; Elsevier Academic Press: Amsterdam, Boston, Heidelberg, 2006; pp. 47-68.
7. Wiener, S.W.; Hoffman, R.S. Nerve agents: a comprehensive review. J. Intensive Care Med., 2004, 19 (1), 22-37.
8. Bajgar, J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem., 2004, 38, 151-216.
9. Balali-Mood, M.; Shariat, M. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J. Physiol. Paris, 1998, 92 (5-6), 375-378.
10. Bajgar, J. Optimal choice of acetylcholinesterase reactivators for antidotal treatment of nerve agent intoxication. Acta Medica. (Hradec Kralove), 2010, 53 (4), 207-211.
11. Albuquerque, E.X.; Pereira, E.F.; Aracava, Y.; Fawcett, W.P.; Oliveira, M.; Randall, W.R.; Hamilton, T.A.; Kan, R.K.; Romano, J.A., Jr.; Adler, M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U S A, 2006, 103 (35), 13220-13225.
12. Buckley, N.A.; Eddleston, M.; Li, Y.; Bevan, M.; Robertson, J. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst. Rev., 2011, (2), CD005085.
13. Kassa, J.; Musilek, K.; Karasova, J.Z.; Kuca, K.; Bajgar, J. Two possibilities how to increase the efficacy of antidotal treatment of nerve agent poisonings. Mini. Rev. Med. Chem., 2012, 12 (1), 24-34.
14. Mercey, G.; Verdelet, T.; Renou, J.; Kliachyna, M.; Baati, R.; Nachon, F.; Jean, L.; Renard, P.Y. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc. Chem. Res., 2012, 45 (5), 756-766.
15. Worek, F.; von der Wellen, J.; Musilek, K.; Kuca, K.; Thiermann, H. Reactivation kinetics of a homologous series of bispyridinium bis-oximes with nerve agent-inhibited human acetylcholinesterase. Arch. Toxicol., 2012, 86 (9), 1379-1386.
16. Tuovinen, K.; Kaliste-Korhonen, E.; Raushel, F.M.; Hanninen, O. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology, 1999, 134 (2-3), 169-178.
17. Lallement, G.; Baille, V.; Baubichon, D.; Carpentier, P.; Collombet, J.M.; Filliat, P.; Foquin, A.; Four, E.; Masqueliez, C.; Testylier, G.; Tonduli, L.; Dorandeu, F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology, 2002, 23 (1), 1-5.
18. Lucic Vrdoljak, A.; Calic, M.; Radic, B.; Berend, S.; Jun, D.; Kuca, K.; Kovarik, Z. Pretreatment with pyridinium oximes improves antidotal therapy against tabun poisoning. Toxicology, 2006, 228 (1), 41-50.
19. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Sheen, R.; Nagelkerke, N. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs pyridostigmine. Toxicol. Appl. Pharmacol., 2007, 219 (2-3), 235-240.
20. Xia, D.Y.; Wang, L.X.; Pei, S.Q. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against Soman poisoning in vivo. Fundam. Appl. Toxicol., 1981, 1 (2), 217-221.
21. Gales, B.J.; Gales, M.A. Pyridostigmine in the treatment of orthostatic intolerance. Ann. Pharmacother., 2007, 41 (2), 314-318.
22. Pope, C.N. In: Toxicology of organophosphate and carbamate compounds; Gupta, Ed.; Elsevier Academic Press: Amsterdam, Boston, Heidelberg, 2006; pp. 271-291.
23. FDA. FDA approves pyridostigmine bromide as pretreatment against nerve gas. http://www.fda.gov/Drugs/EmergencyPrepared ness/BioterrorismandDrugPreparedness/ucm130342.htm 2003 (accessed October 12th, 2012).
24. Dunn, M.A.; Hackley, B.E.; Sidell, F.R. In: Textbook of military medicine: Medical aspects of chemical & biological warfare; Sidell; Takafuji; Franz, Eds. Borden Institute, Walter Reed Army Medical Center: Washington, DC, 1997; pp. 181-196.
25. Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Shafiullah, M.; Kuca, K.; Petroianu, G.A. Pretreatment for acute exposure to diisopropylfluorophosphate: in vivo efficacy of various acetylcholinesterase inhibitors. J. Appl. Toxicol., 2011, 31 (6), 515-523.
26. Petroianu, G.A.; Nurulain, S.M.; Shafiullah, M.; Hasan, M.Y.; Kuča, K.; Lorke, D.E. Usefulness of administration of nonorganophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. Journal of Applied Toxicology, 2012. [Epub ahead of print].
27. Somani, S.M.; Dube, S.N. Physostigmine--an overview as pretreatment drug for organophosphate intoxication. Int. J. Clin. Pharmacol. Ther. Toxicol., 1989, 27 (8), 367-387.
28. Zhao, B.; Moochhala, S.M.; Tham, S.Y. Biologically active components of Physostigma venenosum. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2004, 812 (1-2), 183-192.
29. Grant, S.M.; Langtry, H.D.; Brogden, R.N. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs, 1989, 37 (6), 801-770.
30. Robert, P.H.; Allain, H. Clinical management of agitation in the elderly with tiapride. Eur. Psychiatry, 2001, 16 Suppl 1, 42s-47s.
31. Ferreri, F.; Agbokou, C.; Gauthier, S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J. Psychiatry Neurosci., 2006, 31 (6), 369-376.
32. Raina, P.; Santaguida, P.; Ismaila, A.; Patterson, C.; Cowan, D.; Levine, M.; Booker, L.; Oremus, M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med., 2008, 148 (5), 379-397.
33. Kunes, M.; Svoboda, Z.; Kvetina, J.; Herout, V.; Herink, J.; Bajgar, J. Intestinal single-pass in situ perfusion technique in rat: the influence of L-carnitine on absorption of 7-methoxytacrine. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub., 2005, 149 (2), 433-435.
34. Cingolani, H.E.; Ennis, I.L. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation, 2007, 115 (9), 1090-100.
35. Teiwes, J.; Toto, R.D. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am. J. Hypertens., 2007, 20 (1), 109-117.
36. Chemnitius, J.M.; Haselmeyer, K.H.; Gonska, B.D.; Kreuzer, H.; Zech, R. Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res., 1996, 34 (1-2), 65-72.
37. Pfaffendorf, M.; Bruning, T.A.; Batnik, H.D.; van Zwieten, P.A. The interaction between methylene blue and the cholinergic system. Br. J. Pharmacol., 1997, 122 (1), 95-98.
38. Oz, M.; Lorke, D.E.; Hasan, M.; Petroianu, G.A. Cellular and molecular actions of Methylene Blue in the nervous system. Med. Res. Rev., 2011, 31 (1), 93-117.
39. Kuča, K.; Cabal, J.; Kassa, J. A comparison of the potency of newly developed oximes (K005, K027, K033, K048) and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate sarininhibited rat brain acetylcholinesterase by in vitro methods. J. Toxicol. Environ. Health A, 2005, 68 (8), 677-686.
40. Lorke, D.E.; Hasan, M.Y.; Arafat, K.; Kuca, K.; Musilek, K.; Schmitt, A.; Petroianu, G.A. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropylfluorophosphate. J. Appl. Toxicol., 2008, 28 (4), 422-429.
41. Petroianu, G.A.; Lorke, D.E.; Kalasz, H. Comparison of the ability of pyridinium aldoximes to reactivate human red blood cell acetylcholinesterases inhibited by ethyl-and methyl-paraoxon. Current Organic Chemistry, 2012, 16 (10), 1359-1369.
42. Lorke, D.E.; Nurulain, S.M.; Hasan, M.Y.; Kuca, K.; Musilek, K.; Petroianu, G.A. Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropylfluorophosphate toxicity. J. Appl. Toxicol., 2008, 28 (7), 920-928.
43. Nurulain, S.M.; Lorke, D.E.; Hasan, M.Y.; Shafiullah, M.; Kuca, K.; Musilek, K.; Petroianu, G.A. Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox. Res., 2009, 16 (1), 60-67.
44. Imtiaz, R.; Haugh, G. Analysis of environmental and biologic methyl parathion data to improve future data collection. Environ. Health Perspect., 2002, 110 Suppl 6, 1071-1074.
45. Isbister, G.K.; Mills, K.; Friberg, L.E.; Hodge, M.; O'Connor, E.; Patel, R.; Abeyewardene, M.; Eddleston, M. Human methyl parathion poisoning. Clin. Toxicol. (Phila), 2007, 45 (8), 956-960.
46. Garcia, S.J.; Abu-Qare, A.W.; Meeker-O'Connell, W.A.; Borton, A.J.; Abou-Donia, M.B. Methyl parathion: a review of health effects. J. Toxicol. Environ. Health B Crit. Rev., 2003, 6 (2), 185-210.
47. Rubin, C.; Esteban, E.; Hill, R.H., Jr.; Pearce, K. Introduction--the methyl parathion story: a chronicle of misuse and preventable human exposure. Environ. Health Perspect., 2002, 110 Suppl 6, 1037-1040.
48. Worek, F.; Thiermann, H.; Szinicz, L.; Eyer, P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem. Pharmacol., 2004, 68 (11), 2237-2248.
49. Cox, D.R. Regression models and life tables. J. Royal Statistical Society, 1972, 34, 189-220.
50. Bielavský, J. Analogues of 9-amino-1,2,3,4-tetrahydroacridine. Collect. Czech. Chem. Commun., 1977, 42 (9), 2802-2808.
51. Jun, D.; Kuca, K.; Stodulka, P.; Koleckar, V.; Dolezal, B.; Simon, P.; Veverka, M. HPLC Analysis of HI-6 Dichloride and Dimethanesulfonate-Antidotes against Nerve Agents and Organophosphorus Pesticides. Analytical Letters, 2007, 40 (14), 2783-2787.
52. Jun, D.; Stodulka, P.; Kuca, K.; Koleckar, V.; Dolezal, B.; Simon, P.; Veverka, M. TLC analysis of intermediates arising during the preparation of oxime HI-6 dimethanesulfonate. J. Chromatogr. Sci., 2008, 46 (4), 316-319.
53. Kuča, K.; Bielavský, J.; Cabal, J.; Bielavská, M. Synthesis of a potential reactivator of acetylcholinesterase-1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)propane dibromide. Tetrahedron Letters, 2003, 44 (15), 3123-3125.
54. Korabecny, J.; Musilek, K.; Holas, O.; Binder, J.; Zemek, F.; Marek, J.; Pohanka, M.; Opletalova, V.; Dohnal, V.; Kuca, K. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg. Med. Chem. Lett., 2010, 20 (20), 6093-3095.
55. Korabecny, J.; Musilek, K.; Holas, O.; Nepovimova, E.; Jun, D.; Zemek, F.; Opletalova, V.; Patocka, J.; Dohnal, V.; Nachon, F.; Hroudova, J.; Fisar, Z.; Kuca, K. Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules, 2010, 15 (12), 8804-8812.
56. Lorke, D.E.; Petroianu, G.A. Minireview: does in-vitro testing of oximes help predict their in-vivo action after paraoxon exposure? J. Appl. Toxicol., 2009, 29 (6), 459-469.
57. Miller, S.A.; Blick, D.W.; Kerenyi, S.Z.; Murphy, M.R. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol. Biochem. Behav., 1993, 44 (2), 343-347.
58. Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Sheen, R.; Kuca, K.; Petroianu, G.A. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol., 2007, 27 (5), 482-490.
59. Lorke, D.E.; Kalasz, H.; Petroianu, G.A.; Tekes, K. Entry of oximes into the brain: a review. Curr. Med. Chem., 2008, 15 (8), 743-753.
60. Karasova, J.Z.; Zemek, F.; Musilek, K.; Kuca, K. Time-Dependent Changes of Oxime K027 Concentrations in Different Parts of Rat Central Nervous System. Neurotox. Res., 2012, [Epub ahead of print].